Synedica Tirzepatide 40mg Injection Pen Kit
The Synedica Tirzepatide 40mg Injection Pen Kit is a product containing tirzepatide, a synthetic peptide that acts on two important metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Tirzepatide has been extensively studied in clinical research investigating metabolic conditions, including type 2 diabetes, obesity and related health outcomes.
For readers interested in the broader science behind peptide-based metabolic therapies, see our Tirzepatide research and clinical evidence guide and our GIP and GLP-1 receptor information resource.
Tirzepatide works by activating both GIP and GLP-1 receptors. These pathways are involved in several physiological processes, including glucose regulation, insulin secretion and appetite regulation. Because of its dual-receptor activity, tirzepatide has become the subject of extensive clinical research into metabolic health and weight management.
Clinical Research on Tirzepatide
Clinical trials have evaluated subcutaneous tirzepatide at several different doses and treatment durations. In the phase 3 SURMOUNT-1 trial, researchers evaluated tirzepatide in adults with obesity or overweight accompanied by at least one weight-related health complication. The study included 2,539 adults and compared once-weekly tirzepatide at 5 mg, 10 mg and 15 mg with placebo over 72 weeks.
The study reported substantial reductions in body weight in the tirzepatide treatment groups compared with placebo. These findings provide clinical research evidence concerning tirzepatide as an active pharmaceutical ingredient, but results from a clinical trial should not be interpreted as proof that a separate product has the same formulation, manufacturing quality, safety profile or regulatory status.
For the full published study, see the New England Journal of Medicine — Tirzepatide Once Weekly for the Treatment of Obesity.
Longer-term research has also investigated tirzepatide in people with obesity and prediabetes. A three-year analysis of the SURMOUNT-1 trial followed participants for 176 weeks of treatment, followed by a 17-week off-treatment period. The study reported sustained weight reduction and a lower incidence of progression to type 2 diabetes among participants receiving tirzepatide compared with placebo. Gastrointestinal adverse events were the most frequently reported adverse events and occurred particularly during the dose-escalation period.
Read the complete publication in the New England Journal of Medicine — Tirzepatide for Obesity Treatment and Diabetes Prevention.
Tirzepatide and GIP/GLP-1 Receptor Activity
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Its activity at these receptors has been investigated in relation to glucose regulation, insulin secretion, appetite and other metabolic processes.
The European Medicines Agency provides detailed scientific and regulatory information for the authorised medicine Mounjaro, which contains tirzepatide. The EMA identifies tirzepatide as the active substance and provides access to the medicine’s official product information and assessment documentation.
For additional regulatory and scientific information, see the European Medicines Agency — Mounjaro (tirzepatide).
Product Information
| Specification | Information |
|---|---|
| Product name | Synedica Tirzepatide 40mg Injection Pen Kit |
| Active ingredient | Tirzepatide |
| Amount stated | 40 mg |
| Dosage form | Injection pen kit |
| Pharmacological class | GIP/GLP-1 receptor agonist |
| Route of administration | Injectable |
| Product status | Verify current regulatory status |
| Manufacturer | See verified product/manufacturer documentation |
| Batch number | Refer to individual product packaging |
| Expiry date | Refer to individual product packaging |
| Storage requirements | Follow the verified manufacturer/product instructions |
| Intended purpose | Must correspond with the product’s verified regulatory status and labelling |
Scientific Evidence and Further Reading
The scientific literature provides substantial clinical evidence concerning tirzepatide as an active pharmaceutical ingredient. However, clinical evidence for tirzepatide itself should be distinguished from product-specific evidence concerning a particular formulation, manufacturer, pen device or manufacturing process.
For independent scientific reading, the following resources are relevant:
- Tirzepatide Once Weekly for the Treatment of Obesity — New England Journal of Medicine — phase 3 SURMOUNT-1 research.
- Tirzepatide for Obesity Treatment and Diabetes Prevention — New England Journal of Medicine — longer-term SURMOUNT-1 analysis.
- Mounjaro (tirzepatide) — European Medicines Agency — regulatory and product information for an authorised tirzepatide medicine.
Related Information
Readers can also explore related information available on the Synedica website:
- Tirzepatide Research
- GIP and GLP-1 Research
- Metabolic Health Information
- Weight Management Research
- Peptide Research Information
These internal links should point to genuine, relevant pages containing substantive information rather than being created solely for keyword manipulation.
Important Product Information
The regulatory status, formulation, manufacturing standards, quality controls, concentration, packaging and intended purpose of the Synedica Tirzepatide 40mg Injection Pen Kit https://aquamarine-lapwing-776986.hostingersite.com/tirzepatide-research/ should be verified using applicable product documentation and regulatory information.
Product-specific information such as the manufacturer, batch number, expiry date, concentration per dose, number of doses, storage conditions and licence or authorisation details should only be published when supported by verified product documentation. These details should not be inferred from clinical studies involving other tirzepatide-containing medicines.
The existence of clinical research concerning tirzepatide does not establish that a particular third-party product has equivalent quality, safety, efficacy, formulation or regulatory status to an authorised medicinal product.
This product information is provided for informational purposes only. It is not a prescription, diagnosis or individual treatment recommendation and should not replace advice from a qualified healthcare professional.









Reviews
There are no reviews yet.